Procedure: New Market Authorization Class I
Country: Global Procedure
Version #: 01/08/2024
Author: Daria Kostiuchenko
Editor: Daria Kostiuchenko
ID: GP-MD-VIA-SR
Category: Medical Devices
Validity: Until Change or local NRA
Certified by: Vlad Reznikov
Copyright: Pattern of USA Inc.
SUMMARY
As per FDA device classification, Class I medical devices which fall under the low risks category do not require premarket approval from FDA. However, the device must be registered on the FDA website and must comply with Labeling requirements. Some class I medical devices that fall under the moderate risk category are required for FDA clearance in terms of premarket notification 510(K).
The sponsor should determine which category the device belongs to in EU NRA (EMA). If the device belongs to class I, non-sterile, and non-measuring, then a QMS is not formally required. However, a Post-Market Surveillance (PMS) procedure is required though not audited by a Notified Body (NB, further NRA). The manufacturer must obtain a CE mark, which indicates that the device meets all relevant EU regulatory requirements. To obtain a CE mark, the manufacturer must complete a conformity assessment procedure, which typically includes a technical file review and a clinical evaluation. For those devices that belong to other classes, Quality Management System (QMS) is required, and most companies apply for ISO 13485 standards to achieve QMS compliance. For class I, non-sterile, and non-measuring, there is an audit or MDR/IVDR technical file required.
Market authorization (MA) requirements vary by country, and compliance with local regulations is crucial. It typically involves demonstrating that the device meets safety and performance standards set by the respective health authorities.

Must-Have Requirements, Recognized Standards, and Certifications:
- Device description, including variants
- Technical documentation (MDR/IVDR)
- Instructions for use (IFU)
- Quality Management System (QMS)
- Good Manufacturing Practice (GMP)
- Declaration of Conformity (DoC)
- Risk Management
- Clinical Evidence
- POA
- Substantially equivalent to the predicate device
- MAs in other countries
- CE mark and ISO 13485 in many countries
Nice-to-have:
- IEC 60601
- ISO 14971
- ISO 10993
- Labeling
- Regulatory Compliance and Gap Analysis see GP-PhR-GAP-SR card
- Regulatory Intelligence and Strategic Consulting see GP-PhR-RI-SR card
Typical Gaps and Deficiencies: Understanding of the regulatory pathway and requirements applicable to the device. Incorrect predicate device selection. Inadequate documentation. Rush in submitting the application without being prepared
Implementation Period: Immediately upon approval
Deliverables: Market Authorization (Clearance or Registration), NRA Listing and Establishment registration
PHASE | TASK | TASK | START | DURATION | Fee | KPI | ||
NUMBER | TITLE | OWNER | W/M/Q/Y | in weeks | 3rd Party | Service | State | |
0 | In-house Pre-Submission Activity | |||||||
0.1 | NDA signing or validation | Executor | week 1 | 1 | ||||
0.2 | Contract Closing | MAH | week 1 | 1 | ||||
0.3 | SOW is approved by MAH | MAH | week 1 | 1 | SOW | |||
0.4 | POA issuance and shipping | MAH | week 2 | 1 | ||||
0.5 | Invoice is sent to MAH and paid | MAH | week 3 | 1 | POP | |||
I | Prep and Submission | |||||||
I.1 | Predicate device equivalence, admin. & info set review | Executor | week 4 | 1 | ||||
I.2 | Classify the device (exemption review) | Executor | week 5 | 1 | ||||
I.3 | Technical Documentation review vs. NRA requirements | Executor | week 6 | 2 | ||||
I.4 | Application and supplement documents development | Executor | week 8 | 2 | ||||
I.5 | Approval of the Application | MAH | week 10 | 1 | ||||
I.6 | NRA payment | MAH | week 10 | 1 | ||||
I.7 | Submission of the Application | Executor | week 11 | 1 | Submission | |||
II | Studies | |||||||
II.1 | Сonducting technical, toxicology, electrical, and software tests, as well clinical and suitability studies, if required | Executor | week 12 | 4 | Reports | |||
III | Review and Evaluation | |||||||
III.1 | NRA Application review | NRA | week 16 | 2 | ||||
III.2 | NRA Technical file review | NRA | week 18 | 2 | ||||
III.3 | NRA Lab tests and clinical evaluation review | NRA | week 20 | 2 | ||||
III.4 | NRA Addressing clarifications or queries if so | NRA | week 22 | 1 | ||||
III.5 | Answering with relevant documents from MAH | Executor | week 23 | 1 | ||||
III.6 | NRA Official Response | NRA | week 24 | 1 | ||||
III.7 | NRA Approval (GoTo Ph. IV) or Query (Rpt. Ph. III.5) | NRA | week 25 | 1 | Approval | |||
IV | Approval | |||||||
IV.1 | NRA/NB Conclusion draft verification | Executor | week 26 | 1 | ||||
IV.2 | NRA Conclusion publication | NRA | week 27 | 1 | ||||
IV.3 | State Listing update | Executor | week 28 | 1 | ||||
IV.4 | Reporting to MAH | Executor | week 29 | 1 | Report | |||
F | Final Phase In-house Post-Authorization Activity | |||||||
F.1 | Service Acceptance Certificate signing | MAH | week 30 | 1 | ||||
F.2 | Final Invoice | Executor | week 30 | 1 | ||||
F.3 | Final Payment | MAH | week 31 | 1 | ||||
F.4 | Contract Termination | Executor | week 31 | 1 | ||||
F.5 | Archiving and limiting access | Executor | week 32 | 1 | Archiving |
Feel free to submit a Request for Proposal (RFP) for a specific country or territory to info@patternofusa.com